Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder with progressive damage to brain cells. It is the leading cause of dementia worldwide that is characterized by impairment of memory and eventually by reasoning and perception disturbances. No curative treatment for dementia is currently available. With the progress of RNA sequencing and transcriptome analysis, the discovery of non-protein coding RNAs expands our knowledge about the genome. Long non-coding RNAs (lncRNAs) which are involved in a wide variety of biological processes as regulatory molecule, have been the focus of much recent research. In this review, we focus on the emerging roles of these lncRNAs in the pathology of Alzheimer’s disease. Their expressions are brain-specific and dysregulated in the patient and animal model. Here, we will summarize the pathological features influenced by lncRNAs and therefore provide an lncRNA point-of-view on AD. This should stimulate new research directions and therapeutic options considering lncRNAs as novel prognostic markers and therapeutic targets.
Keywords: Alzheimer’s disease, Drug discovery, Long non-coding RNA, Regulator molecular.
Current Topics in Medicinal Chemistry
Title:Long non-coding RNAs in Alzheimer’s disease
Volume: 16 Issue: 5
Author(s): Zijian Zhang
Affiliation:
Keywords: Alzheimer’s disease, Drug discovery, Long non-coding RNA, Regulator molecular.
Abstract: Alzheimer’s disease (AD) is a neurodegenerative disorder with progressive damage to brain cells. It is the leading cause of dementia worldwide that is characterized by impairment of memory and eventually by reasoning and perception disturbances. No curative treatment for dementia is currently available. With the progress of RNA sequencing and transcriptome analysis, the discovery of non-protein coding RNAs expands our knowledge about the genome. Long non-coding RNAs (lncRNAs) which are involved in a wide variety of biological processes as regulatory molecule, have been the focus of much recent research. In this review, we focus on the emerging roles of these lncRNAs in the pathology of Alzheimer’s disease. Their expressions are brain-specific and dysregulated in the patient and animal model. Here, we will summarize the pathological features influenced by lncRNAs and therefore provide an lncRNA point-of-view on AD. This should stimulate new research directions and therapeutic options considering lncRNAs as novel prognostic markers and therapeutic targets.
Export Options
About this article
Cite this article as:
Zhang Zijian, Long non-coding RNAs in Alzheimer’s disease , Current Topics in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1568026615666150813142956
DOI https://dx.doi.org/10.2174/1568026615666150813142956 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Prion Protein Oligomerization
Current Alzheimer Research Anti-Tumorigenic Effects of Resveratrol in Lung Cancer Cells Through Modulation of c-FLIP
Current Cancer Drug Targets Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Protein & Peptide Letters The High Throughput Biomedicine Unit at the Institute for Molecular Medicine Finland: High Throughput Screening Meets Precision Medicine
Combinatorial Chemistry & High Throughput Screening CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer
Current Medicinal Chemistry Cell Death in Mammalian Development
Current Pharmaceutical Design Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides
CNS & Neurological Disorders - Drug Targets Nongenomic Actions of Thyroid Hormones: From Basic Research to Clinical Applications. An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects
Current Medicinal Chemistry Alpha-2 Adrenoceptor Ligands and Opioid Drugs: Pharmacological Interactions of Therapeutic Interest
Current Neuropharmacology Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry Preface
Current Radiopharmaceuticals Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry